This mind-blowing study revealed how berberine lowers LDL cholesterol through a mechanism that’s completely different from ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny—and what nuances do you need to know? Let’s dig in.

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...